Asieris(SH:688176) Zheng Quan Zhi Xing·2025-06-20 09:44Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. has announced the cancellation of 1.8305 million shares of restricted stock that were granted but not yet vested under the 2022 Restricted Stock Incentive Plan [1][6] Summary by Sections Approval Procedures - The board of directors approved the incentive plan and related matters during meetings held on July 27, 2022, and subsequent meetings [2][3][4] - The supervisory board verified the incentive plan and provided relevant opinions [2][5] Cancellation Details - The cancellation of the restricted stock is due to 8 incentive recipients leaving the company, resulting in 1.6888 million shares being forfeited, and 4 recipients failing to meet performance criteria, leading to an additional 0.1304 million shares being canceled [6] - In total, 1.8305 million shares of restricted stock will be canceled [6] Impact on the Company - The cancellation of the restricted stock will not have a substantial impact on the company's financial status or operational results, nor will it affect the stability of the management team or the implementation of the incentive plan [6] Supervisory Board Opinion - The supervisory board agrees that the cancellation of the restricted stock complies with relevant laws and regulations and does not harm shareholder interests [6] Legal and Financial Advisor Opinions - Legal opinions confirm that the cancellation is in accordance with the Company Law, Securities Law, and relevant regulations [6] - The independent financial advisor supports that the cancellation has received necessary approvals and does not harm the interests of the company or its shareholders [6]